TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0

CUSIP: 89422GAA5

Q4 2025 13F Holders as of 31 Dec 2025

Type / Class
Debt / NOTE 2.250% 3/0
Market price (% of par)
142.2%
Total 13F principal
$316,740,000
Principal change
+$44,363,646
Total reported market value
$451,855,340
Number of holders
33
Value change
+$76,789,651
Number of buys
20
Number of sells
12

Quarterly Holders Quick Answers

What is CUSIP 89422GAA5?
CUSIP 89422GAA5 identifies 89422GAA5 - TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 as of Q4 2025

As of 31 Dec 2025, TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 was held by 33 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $316,740,000 in principal (par value) of the bond. The largest 10 bondholders included Linden Advisors LP, Context Capital Management, LLC, D. E. Shaw & Co., Inc., FMR LLC, MILLENNIUM MANAGEMENT LLC, ADVENT CAPITAL MANAGEMENT /DE/, TENOR CAPITAL MANAGEMENT Co., L.P., LORD, ABBETT & CO. LLC, Affinity Asset Advisors, LLC, and SHENKMAN CAPITAL MANAGEMENT INC. This page lists 33 institutional bondholders reporting positions for the Q4 2025 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.